Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Holding AU:IXC?
Track your performance easily
IXC Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.06 - AU$0.34
Previous CloseAU$0.07
Volume8.59K
Average Volume (3M)36.21K
Market Cap
AU$5.41M
Enterprise Value-AU$23.93M
Total Cash (Recent Filing)AU$29.34M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Feb 13, 2025EPS EstimateN/A
Last Dividend Ex-Date
Dec 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. Volume16,723
30 Day Avg. Volume36,211
Standard Deviation0.19
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Invex Therapeutics Ltd. News
PremiumCompany Announcements
Invex Therapeutics Embraces Corporate Governance Standards
PremiumCompany Announcements
Invex Therapeutics Cuts Losses, Skips DividendPremiumCompany Announcements
Invex Therapeutics Shareholder Voting Power Shifts
PremiumCompany Announcements
Invex Therapeutics Finalizes Key Clinical TrialPremiumCompany Announcements
Invex Therapeutics Announces Director’s Final Notice
PremiumCompany Announcements
Invex Therapeutics Options Cease Trading
PremiumCompany Announcements
Invex Therapeutics Bids Farewell to Board Member
PremiumCompany Announcements
Invex Therapeutics Advances Exenatide DevelopmentOptions Prices
Currently, No data available
---
Ownership Overview
4.87%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
95.13% Public Companies and
Individual Investors
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.06 and its highest was AU$0.34 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Feb 13, 2025 which is in 146 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Aug 22, 2024. The company reported AU$0.006 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.006.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.19 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of AU$0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
---
Invex Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.00%
12-Months-Change
Fundamentals
Return on Equity
-12.20%
Trailing 12-Months
Asset Growth
-73.16%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.
---
Technical Analysis
---